Respiratory Virus Vaccines Market Size to Hit Around US$ 14.6 Bn by 2030

According to Vision Research Reports, the global respiratory virus vaccines market size is projected to hit around US$ 14.6 billion by 2030 from US$ 3.2 billion in 2020, growth is expanding at a CAGR of 8.1% from 2021 to 2030.

Rise in prevalence of respiratory illnesses and demand for newer vaccines for the prevention of respiratory infections, and large number of pharmaceutical companies participating in the race to develop vaccine for the novel coronavirus are major factors projected to boost the respiratory virus vaccines market during the forecast period.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38194

A vaccine is a biological preparation that is used to provide acquired immunity against numerous harmful pathogens. It is administered in order to prevent the vulnerable population against specific disease. It contains an agent, i.e. bacteria or virus strain, which causes a particular disease in a weakened or killed form.

Immunization Programs Significantly Reduce Mortality Rates for Measles

The World Health Organization (WHO) claims that immunization has become an important tool for innovation in measles vaccines. With the help of immunization, several million infants are being vaccinated against measles, thus lowering mortality rates worldwide. Companies in the respiratory virus vaccines market are developing promising vaccines that protect the health of individuals from tuberculosis and influenza. They are intensifying their R&D capabilities to develop neutralizing antibodies and therapeutic respiratory virus vaccines that can generate value-grab opportunities for manufacturers.

There is a growing demand for needle-free vaccine administration to suit the needs of adolescents, pregnant women, and other age groups. Moreover, there is a need for robust vaccine storage and supply chains that hold promising potentials to transform immunization programs in the upcoming decade. Thus, timely access to reliable data is found to provide exciting opportunities for companies in the respiratory virus vaccines market.

Scope of The Report

Large Investments Play Key Role in Validated Efficacy of Mumps Vaccines

A research done by Emory Vaccine Center and the Centers for Disease Control and Prevention indicates that immunity against mumps virus appears to be insufficient among a fraction of college-aged individuals who were previously vaccinated in their childhood. Thus, companies in the respiratory virus vaccines market are increasing efforts to better understand the immune response to mumps and mumps vaccines. In the past decade, it has been observed that several mumps outbreaks have occurred among sports teams, college students, and close-knit communities in the U.S. Hence, pharmaceutical companies are focusing on developing effective mumps vaccines to lower the rate of mumps outbreaks.

Lack of strong immune response pertaining to mumps vaccine has emerged as a challenge for companies in the respiratory virus vaccines market. Manufacturers are directing large investment in clinical trials to demonstrate the safety and efficacy of mumps vaccines.

Drivers and Restrains

The analysis report has incorporated the analysis of various factors that augment the market’s growth. It constitutes trends, restraints, and drivers that remodel the market in either a positive or negative manner. This section additionally provides the scope of various segments and applications that may probably influence the market within the future. The elaborated info is predicated on current trends and historic milestones. This section additionally provides an analysis of the amount of production regarding the world market and regarding every kind from 2022-2030.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38194

Impacts of the COVID-19 Pandemic

Most industries across the world have been negatively impacted over the last few months. This can be attributed to significant disruptions experienced by their respective manufacturing and supply-chain operations as a result of various precautionary lockdowns, as well as other restrictions that were enforced by governing authorities across the globe. The same applies to the global Respiratory Virus Vaccines market. Moreover, consumer demand has also subsequently reduced as individuals are now more keen on eliminating non-essential expenses from their respective budgets as the general economic status of most individuals have been severely affected by this outbreak. These aforementioned elements are expected to burden the revenue trajectory of the global Respiratory Virus Vaccines market over the forecast timeline. However, as respective governing authorities begin to lift these enforced lockdowns, the global Respiratory Virus Vaccines market is expected to recover accordingly.

Report Highlights

In terms of type, the global respiratory virus vaccines market has been classified into inactivated/killed vaccines, live-attenuated vaccines, and recombinant vaccines. The inactivated/killed vaccines segment accounted for a prominent share of the global market in 2020. The segment is estimated to be driven by the launch of new vaccines and robust research programs for the development of inactivated vaccine for COVID-19. 

Based on route of administration, the global respiratory virus vaccines market has been categorized into intramuscular, intranasal, and subcutaneous. The intramuscular segment held a major share of the global market in 2019.

In terms of indication, the global respiratory virus vaccines market has been classified into influenza, measles, mumps & rubella, coronavirus disease (COVID-19), and others. The influenza segment held a notable share of the global market in 2020. The segment is likely to be driven an increase in number of influenza patients and a rise in focus on vaccination programs for children. 

Based on age group, the global respiratory virus vaccines market has been divided into pediatric and adults. The pediatric segment accounted for a leading share of the global market in 2020. 

In terms of end user, the global respiratory virus vaccines market has been classified into physician’s office, hospitals, clinics, pharmacies/stores, and others. The physician’s office segment held a significant share of the global market in 2020.

By geograpghy, the North America held a major share of the global respiratory virus vaccines market in 2020. Increase in demand for effective vaccination, rise in number of patients with influenza, and favourable government support for adult and pediatric vaccination are key factors driving the market in the region. According to the Centers for Disease Control and Prevention (CDC), seasonal influenza accounts for over 20,000 deaths in the U.S. each year. 

Europe held the second-largest share of the global respiratory virus vaccines market in 2020. The expansion of the respiratory virus vaccines market in the region can be attributed to increase in investment in R&D activities to develop vaccine against the novel coronavirus through partnerships between pharmaceutical companies.

Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2017 to 2019.

The analysts have provided a comprehensive analysis of the competitive landscape of the global respiratory virus vaccines market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation expected to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.

Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.

Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users) and other segments.

• Company Overview
• Company Market Share/Positioning Analysis
• Product Offerings
• Financial Performance
• Recent Initiatives
• Key Strategies Adopted by Players
• Vendor Landscape
• List of Suppliers
• List of Buyers

Key players operating in the global respiratory virus vaccines market include CSL Limited, Sanofi, AstraZeneca, Merck & Co., Inc., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Bharat Biotech, and Sinovac Biotech Ltd.

Market Segmentation

By Type

• Inactivated/Killed Vaccines
• Live-attenuated Vaccines
• Recombinant Vaccines

By Route of Administration

• Intramuscular
• Intranasal
• Subcutaneous

By Indication

• Influenza
• Measles, Mumps & Rubella
• Coronavirus Disease (COVID-19)
• Others

By Age Group

• Pediatric
• Adults

By End User

• Physician’s Office
• Hospitals
• Clinics
• Pharmacies/Stores
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38194

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://qyresearchmedical.com/